First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hospital Sydney.OPTIMAL-e will evaluate TLX597-Tx in earlier ...

First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof.Patient care and research delivered in collaboration with the ...

The Defense Secretary said the push to provide this care was not about artificial enhancements. “It’s about restoring and ...

Testosterone deficiency screening and replacement therapy will soon be on offer for active-duty service members as a military ...

In a new research report, scientists at Johns Hopkins University School of Medicine and Johns Hopkins Kimmel Cancer Center ...

A new treatment combination - Keytruda plus Padcev - is now approved for use before and after bladder‑removal surgery, ...

Former President Joe Biden will publish a memoir, "Promise Me, America," which he says will touch upon everything from the economy to his decision to drop his bid for reelection.The memoir is ...

Prostate cancer is often resistant to immunotherapy, which harnesses a person's immune system to recognize and destroy tumors ...

Joe Biden has shared a personal health update while announcing his upcoming memoir. The former president said his cancer ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that its MRI-guided, AI-powered, Robotically-Driven and Incisionless TULSA Procedure™ will be ...

Russ Reed finally got his cancer drug, but others mired in red tape. “There are a lot of people who are going to die ...

Less than a month after locking down a lease for a new U.S. headquarters, radiotherapy outfit AdvanCell is poised to push its ...